CEO Message

About F&T

CEO
Kim Kwang

Future & Tech is a human-centric company committed to the vision of “improving human safety, happiness, and quality of life.” Under this very vision, we aim to support a “healthy 100-years of life,” by addressing aging-related diseases, cancer, muscular disorders, as well as diseases that are rare and lack current treatments. The company is also dedicated to finding solutions for zoonotic infectious diseases caused by viruses such as avian influenza and the coronavirus, as well as tackle global challenges faced by mankind, including food shortages driven by rapid population growth. Future & Tech was founded in 2018 at the Bio InnoBiz Center within the Korea Research Institute of Bioscience and Biotechnology (KRIBB). We have consistently built on our R&D expertise under the mission to develop new immune-based therapies for both humans and animals. As a result, we have successfully developed two core platform technologies: STOM-IC, a novel technology to isolate and cultivate non-culturable microorganisms, and GOSTα, a probiotic cell-surface protein expression technology. Leveraging these achievements, we continue to develop active immunotherapies for both humans and animals. The core values of Future & Tech’s immunotheraphy development are as follows. First, we aim to develop safe active immunotherapies that have no side-effects. Second, the developed therapies shall ensure sustained therapeutic effectiveness for the targeted diseases.

Third, we aim to develop widely accessible treatments through low-cost, simplified production processes. To achieve these goals, Future & Tech actively supports researchers to enhance their expertise, encouraging the spirit to voluntarily challenge the status quo, and transparently evaluating research outcomes through the Technology Advisory Committee, thereby instilling the sense of ownership and accountability. Additionally, we implement a systematic business management system with performance-based rewards for research outcomes, where our members find fulfillment in contributing to ‘enhanced well-being and quality of life of the mankind.’ Based on continuous research in specialized immunotherapy and vaccine development, Future & Tech remains committed to becoming a global leader through its mission of delivering next-generation active immunotherapy solutions.

CEO
Hong Seungpyo

About F&T

CEO Message

Cookie notice

Cookie Consent Settings